Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

Omer Karrar; Maymona Abdelmagid; Masooma Rana; Moazah Iftikhar; Kristen McCullough; Aref Al-Kali; Hassan B Alkhateeb; Kebede H Begna; Michelle A Elliott; Abhishek Mangaonkar; Antoine Saliba; Mehrdad Hefazi Torghabeh; Mark R Litzow; William Hogan; Mithun Shah; Mrinal M Patnaik; Animesh Pardanani; Talha Badar; Hemant Murthy; James Foran; Jeanne Palmer; Lisa Sproat; Nandita Khera; Cecilia Arana Yi; Ayalew Tefferi; Naseema Gangat

doi:10.1002/ajh.27180

Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

Am J Hematol. 2024 Feb;99(2):E63-E66. doi: 10.1002/ajh.27180. Epub 2023 Dec 15.

Authors

Omer Karrar¹, Maymona Abdelmagid¹, Masooma Rana¹, Moazah Iftikhar¹, Kristen McCullough¹, Aref Al-Kali¹, Hassan B Alkhateeb¹, Kebede H Begna¹, Michelle A Elliott¹, Abhishek Mangaonkar¹, Antoine Saliba¹, Mehrdad Hefazi Torghabeh¹, Mark R Litzow¹, William Hogan¹, Mithun Shah¹, Mrinal M Patnaik¹, Animesh Pardanani¹, Talha Badar², Hemant Murthy², James Foran², Jeanne Palmer³, Lisa Sproat³, Nandita Khera³, Cecilia Arana Yi³, Ayalew Tefferi¹, Naseema Gangat¹

Affiliations

¹ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
² Division of Hematology, Mayo Clinic, Jacksonville, Florida, USA.
³ Division of Hematology, Mayo Clinic, Scottsdale, Arizona, USA.

PMID: 38100217
DOI: 10.1002/ajh.27180

Abstract

Overall survival and response rates of 270 patients with newly diagnosed acute myeloid leukemia receiving venetoclax (Ven) plus hypomethylating agent, stratified by Ven dosing schedule (Cycle 1 Ven 14 vs. 21 vs. 28 days).

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Bridged Bicyclo Compounds, Heterocyclic* / adverse effects
Humans
Leukemia, Myeloid, Acute* / drug therapy
Sulfonamides / adverse effects

Substances

venetoclax
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides